Skip to main content

Table 3 Medical resource use for disease management by health state (Source of costs: NHS reference costs 2013–2014 [29])

From: Cost-effectiveness analysis of bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP) in patients with previously untreated mantle cell lymphoma

 

On treatment (first- or second-line)

Stable disease (off treatment)

At time of progression

Progressed

Unit cost

Full blood count

3 per treatment cycle

1 per 2–3 monthsa

1

0

£3.00

Biochemistry

3 per treatment cycle

1 per 2–3 monthsa

1

0

£1.18

Blood glucose

3 per treatment cycle

0

0

0

£1.18

Computerised tomography scan

In treatment Cycles 1, 3 and 6

0

1

0

£80.00

Haematologist visit

In treatment Cycles 1, 3 and 6

1 per 2–3 monthsa

1

1 per 2–3 monthsa

£150.06

  1. Abbreviations: NHS National Health Service
  2. aThis has been applied to the model as once every 11 weeks